The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. (Q35640348)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

review article

1 reference

title

The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

author name string

M H Tan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

M J Prince

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

P P Erickson

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

publication date

1 March 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

17 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

page(s)

133-156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

17 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Is sulphonylurea therapy effective long term? A 3-year study with gliclazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Repaglinide versus glyburide: a one-year comparison trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Advances in understanding of the role of lecithin cholesterol acyltransferase (LCAT) in cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

Effect of thiazolidinediones on high-density lipoprotein subfractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1462-8902.2004.00325.X

10.1111/J.1462-8902.2004.00325.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14746579%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

1 reference